Laura Prosser

Head of Finance at Proveca Ltd

Laura Prosser has a diverse work experience in finance and accounting. Laura is currently the Head of Finance at Proveca Ltd since May 2023. Previously, they worked at Fact3 for over a decade as a Portfolio Finance Director / Controller. In that role, they managed a portfolio of clients from various sectors, including biotech, manufacturing, trade associations, and professional services. Their responsibilities included financial management, preparation of management accounts, working capital management, forecasting, and overseeing a team. Additionally, Laura was involved in strategic decision-making at Fact3, which experienced significant growth during their tenure. Prior to that, Laura worked at Leonherman Accountants & Business Advisors as an Accounts & Audit Trainee/Senior. In this role, they gained experience in bookkeeping, VAT returns, payroll processing, management accounts, audits, and tax returns for owner-managed businesses.

Laura Prosser obtained their GCSE from Standish Community High School, where they studied English, Maths, Science, French, Spanish, IT, RE, PE, Statistics, Geography, and Textiles from 1996 to 2001. Laura then pursued A Levels in Maths, Law, Business Studies, and Psychology at Runshaw College from 2001 to 2003. Following that, Laura attended The University of Manchester in 2003 to 2004, where they focused on Accountancy & Law. Laura furthered their education at Kaplan Financial Training from 2004 to 2008, obtaining the ACCA degree in Accounting. In September 2008, they obtained the FCCA certification from ACCA.

Location

Manchester, United Kingdom

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices


Proveca Ltd

Proveca Ltd is a pharmaceutical company specialising in identifying, researching and licensing off-patent medicines with unmet priority health care needs, with a focus on the paediatric market. By developing the necessary formulations and clinical data required to obtain a Paediatric Use Marketing Authorisation (PUMA) these drugs will benefit froma period of 10 years' market protection (8 years of data and market protection plus 2 further years of market protection). In addition, where appropriate, Orphan Drug status (Orphan Drug) will be sought which affords a period of 10 years' market exclusivity to run concurrently.Value will be realised through commercialisation of the licensed medicine or an outright sale of the licence to a larger pharmaceutical company.


Employees

11-50

Links